Itero Biopharmaceuticals, LLC is a specialty biopharmaceutical company focused on the cost-efficient development and commercialization of protein therapeutics. Led by an experienced team with an extensive track record of successful execution in the field of recombinant DNA-produced medicines, including monoclonal antibodies, the company leverages its internal development and commercialization expertise to reduce risk and maximize value rapidly. Itero aims to efficiently generate a flow of meaningful therapeutic products for commercialization.
Itero's first product, recombinant follicle stimulating hormone (rFSH) was partnered in July 2010 with Watson Pharmaceuticals, Inc., which is currently developing it for the treatment of female infertility. Upon successful development and regulatory approval, the product is planned to be commercialized by Watson's branded commercial organization on a global basis, where it will compete in what is currently a growing $1.2 billion market.
With a focus on differentiated products, rather than specific therapeutic areas, technology, indications or platforms, Itero is currently seeking and evaluating further product opportunities for in-licensing or acquisition, where the company can quickly reduce development risk and maximize value while completing development and commercialization with partners and on its own.
